🚀 VC round data is live in beta, check it out!
HK inno.N Valuation Multiples
Discover revenue and EBITDA valuation multiples for HK inno.N and similar public comparables like Chabiotech, Lepu Biopharma, Keqian Biology, AprilBio and more.
HK inno.N Overview
About HK inno.N
HK Inno N Corp manufactures pharmaceutical products.
Founded
N/A
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$1B
HK inno.N Financials
HK inno.N reported last 12-month revenue of $736M and EBITDA of $108M.
In the same LTM period, HK inno.N generated $345M in gross profit, $108M in EBITDA, and $55M in net income.
Revenue (LTM)
HK inno.N P&L
In the most recent fiscal year, HK inno.N reported revenue of $606M and EBITDA of $85M.
HK inno.N expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $736M | XXX | $606M | XXX | XXX | XXX |
| Gross Profit | $345M | XXX | $294M | XXX | XXX | XXX |
| Gross Margin | 47% | XXX | 49% | XXX | XXX | XXX |
| EBITDA | $108M | XXX | $85M | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 14% | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 10% | XXX | XXX | XXX |
| Net Profit | $55M | XXX | $42M | XXX | XXX | XXX |
| Net Margin | 7% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | — | — | $253M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
HK inno.N Stock Performance
HK inno.N has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
HK inno.N's stock price is $38.46.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | (1.3%) | XXX | XXX | XXX | $1.47 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHK inno.N Valuation Multiples
HK inno.N trades at 1.8x EV/Revenue multiple, and 12.2x EV/EBITDA.
EV / Revenue (LTM)
HK inno.N Financial Valuation Multiples
As of March 7, 2026, HK inno.N has market cap of $1B and EV of $1B.
Equity research analysts estimate HK inno.N's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
HK inno.N has a P/E ratio of 19.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 12.2x | XXX | 15.5x | XXX | XXX | XXX |
| EV/EBIT | 17.0x | XXX | 22.2x | XXX | XXX | XXX |
| EV/Gross Profit | 3.8x | XXX | 4.5x | XXX | XXX | XXX |
| P/E | 19.9x | XXX | 26.2x | XXX | XXX | XXX |
| EV/FCF | 66.6x | XXX | (98.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified HK inno.N Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
HK inno.N Margins & Growth Rates
HK inno.N's revenue in the last 12 month grew by 6%.
HK inno.N's rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
HK inno.N's rule of X is 30% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
HK inno.N Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Growth | 16% | XXX | 23% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 21% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 30% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 18% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2% | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 39% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
HK inno.N Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Chabiotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Lepu Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Keqian Biology | XXX | XXX | XXX | XXX | XXX | XXX |
| AprilBio | XXX | XXX | XXX | XXX | XXX | XXX |
| GNI Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
HK inno.N M&A Activity
HK inno.N acquired XXX companies to date.
Last acquisition by HK inno.N was on XXXXXXXX, XXXXX. HK inno.N acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by HK inno.N
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHK inno.N Investment Activity
HK inno.N invested in XXX companies to date.
HK inno.N made its latest investment on XXXXXXXX, XXXXX. HK inno.N invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by HK inno.N
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout HK inno.N
| Where is HK inno.N headquartered? | HK inno.N is headquartered in South Korea. |
| Who is the CEO of HK inno.N? | HK inno.N's CEO is Dal-Won Kwak. |
| Is HK inno.N publicly listed? | Yes, HK inno.N is a public company listed on Korea Exchange. |
| What is the stock symbol of HK inno.N? | HK inno.N trades under 195940 ticker. |
| When did HK inno.N go public? | HK inno.N went public in 2021. |
| Who are competitors of HK inno.N? | HK inno.N main competitors are Chabiotech, Lepu Biopharma, Keqian Biology, AprilBio. |
| What is the current market cap of HK inno.N? | HK inno.N's current market cap is $1B. |
| What is the current revenue of HK inno.N? | HK inno.N's last 12 months revenue is $736M. |
| What is the current revenue growth of HK inno.N? | HK inno.N revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of HK inno.N? | Current revenue multiple of HK inno.N is 1.8x. |
| Is HK inno.N profitable? | Yes, HK inno.N is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of HK inno.N? | HK inno.N's last 12 months EBITDA is $108M. |
| What is HK inno.N's EBITDA margin? | HK inno.N's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of HK inno.N? | Current EBITDA multiple of HK inno.N is 12.2x. |
| What is the current FCF of HK inno.N? | HK inno.N's last 12 months FCF is $20M. |
| What is HK inno.N's FCF margin? | HK inno.N's last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of HK inno.N? | Current FCF multiple of HK inno.N is 66.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.